Cannabis Rescheduling

Wyoming Rejects Trump Administration’s Schedule III Cannabis Listing; Keeps It Schedule I

Wyoming Attorney General Keith G. Kautz announced that he won’t loosen restrictions on cannabis after there was little public interest in doing so.

Cannabis Prohibition Interests Don’t ‘Systemically Align’ With American Public, DOJ Says

The Department of Justice argued that anti-rescheduling groups attempting to stay a Schedule III order have ‘pocketbook interests’ in prohibition.

‘DEA Comes Out Swinging in Cannabis Rescheduling Hearing' Leads CBT’s Top Stories in June

CBT provided an in-the-courtroom analysis of the DEA’s first witness’s testimony in support of the Schedule III proposed rule.

Prohibitionists Punch Back at Cannabis Rescheduling Hearing

Anti-rescheduling participants who oppose the Schedule III proposal attempt to expose flaws in a scientific and medical evaluation and discredit DEA witnesses.

DEA Comes Out Swinging in Cannabis Rescheduling Hearing

The government argued in support of currently accepted medical use; anti-rescheduling parties attempted to poke holes in the Schedule III recommendation.

DEA Plans to Call Pain Management Doctor, FDA Official to Testify at Cannabis Reschedule Hearing

The Drug Enforcement Administration filed a prehearing statement summarizing its two proposed witnesses’ testimony.

DEA Judge Sets Cannabis Hearing Schedule, Won’t Consider More Participants

The administrative law judge declined to consider pleas from non-parties to participate in the rescheduling hearing for the proposed Schedule III rule.

Should DEA’s One-Sided Cannabis Rescheduling Hearing Be Reason for Concern?

The government may lack a sufficient administrative record to defend a Schedule III decision in judicial review without any pro-rescheduling participants.

DEA Names 7 Anti-Rescheduling Parties for Cannabis Hearing, Zero Pro Parties

Derek C. Julius will be the DEA’s chief administrative law judge to oversee the hearing of a proposed rule to reclassify cannabis as a Schedule III drug.

Feds Haven’t Provided ‘Clear Guidance, Feedback’ to Ohio on Cannabis Rescheduling

The state’s Division of Cannabis Control ‘doesn’t have a lot of great answers’ for its dual-licensed operators, the department’s legal counsel says.

Glass House Brands Deconsolidates Dual-Use Business, Applies for Uplisting of Shares to NYSE

The U.S. cannabis company plans to list its subordinate voting shares on the New York Stock Exchange.

Anti-Rescheduling Parties Ask Court to Stay Schedule III Cannabis Order

A national drug screening association and a private pharmaceutical cannabinoid development company argue they’ll suffer irreparable harm.

Page 1 of 19

Next Page